Daniel A Vallera
Affiliation: University of Minnesota
- Vallera D, Chen H, Sicheneder A, Panoskaltsis Mortari A, Taras E. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009;33:1233-42 pubmed publisher..DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation. ..
- Schmohl J, Todhunter D, Taras E, Bachanova V, Vallera D. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins (Basel). 2018;10: pubmed publisher....
- Oh S, Ohlfest J, Todhunter D, Vallera V, Hall W, Chen H, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol. 2009;95:331-342 pubmed publisher..Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study...
- Vallera D, Oh S, Chen H, Shu Y, Frankel A. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther. 2010;9:1872-83 pubmed publisher..Because 2219KDEL7mut immunogenicity was significantly reduced and the drug was highly effective in vivo, we can now give multiple drug treatments with targeted toxins in future clinical trials. ..
- Schmohl J, Gleason M, Dougherty P, Miller J, Vallera D. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol. 2016;11:353-61 pubmed publisher....
- Vallera D, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl J, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22:3440-50 pubmed publisher..These qualities are ideal for NK cell therapy of myeloid malignancies or targeting antigens of solid tumors. Clin Cancer Res; 22(14); 3440-50. Â©2016 AACRSee related commentary by Talmadge, p. 3419. ..
- Schmohl J, Vallera D. CD133, Selectively Targeting the Root of Cancer. Toxins (Basel). 2016;8: pubmed publisher..In this review, we discuss the development and current status of these CD133 associated biological agents. Together, they show exceptional promise by specific and efficient CSC elimination. ..